Vertex Pharmaceuticals Inc. — 2020 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020. This annual filing also reports fourth-quarter results; it is not a standalone quarterly filing. Amounts below are U.S. dollars.
Business context
Vertex is a biotechnology company focused on specialty medicines. Its four marketed cystic fibrosis (CF) medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. The business remains heavily dependent on CF products. Vertex is expanding research into genetic and cell therapies and other diseases, including sickle cell disease, beta thalassemia, type 1 diabetes, AAT deficiency and APOL1-mediated kidney disease.
Financial performance and liquidity
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Total revenue | $6.206 billion | $4.163 billion | +49% |
| Net product revenue | $6.203 billion | $4.161 billion | +49% |
| Income from operations | $2.856 billion | $1.198 billion | +139% |
| Net income attributable to Vertex | $2.712 billion | $1.177 billion | +130% |
| Diluted EPS | $10.29 | $4.51 | +$5.78 |
| Operating cash flow | $3.254 billion | $1.569 billion | +$1.684 billion |
Revenue growth was principally driven by TRIKAFTA’s U.S. launch in late 2019 and KAFTRIO’s European launch in 2020. 2020 product revenue by brand was TRIKAFTA/KAFTRIO $3.864 billion, SYMDEKO/SYMKEVI $629 million, ORKAMBI $908 million and KALYDECO $803 million. Ex-U.S. product revenue was $1.4 billion, versus $1.1 billion in 2019.
Operating expenses were $3.349 billion, up 13%. Research and development expense was $1.830 billion (+4%), sales, general and administrative expense was $770 million (+17%), and cost of sales was $736 million. Cost of sales was approximately 12% of product revenue, implying a product gross margin of about 88%; operating margin was about 46%, compared with about 29% in 2019. Net margin was about 44%, versus about 28% in 2019.
Cash, cash equivalents and marketable securities totaled $6.659 billion at year-end, up from $3.808 billion. Working capital was $6.256 billion. Cash provided by operations was $3.254 billion; purchases of property and equipment were $260 million, implying approximate free cash flow of $2.994 billion before other investing items. Vertex had no principal or interest outstanding on its revolving credit facilities. It had $581 million of finance lease liabilities and $361 million of operating lease liabilities. The company reported $8.687 billion in shareholders’ equity.
Material changes and unusual items
- TRIKAFTA/KAFTRIO revenue rose to $3.864 billion from $420 million as the product expanded from the U.S. into Europe. Revenue for SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO declined, primarily as U.S. patients switched to TRIKAFTA, partly offset by international access and label expansions.
- Other income included $296 million of net gains, primarily from changes in fair value and sales of strategic equity investments. Such gains may fluctuate with biotechnology share prices and boosted reported earnings.
- The 2020 tax provision was $405 million, with an effective tax rate of approximately 13%. The rate reflected discrete benefits, including a $209 million deferred tax benefit associated with an intellectual-property transfer to the U.K., as well as other items. Vertex used substantially all of its previously benefited U.S. net operating losses, so a larger portion of future tax provision is expected to be payable in cash.
- Research and development included $184.6 million of collaboration and asset-acquisition expenses. Development spending increased with the expanding pipeline; management expects development and SG&A expenses to rise further in 2021.
- Vertex repurchased $539 million of common stock during 2020. A new program authorized up to $500 million of repurchases through December 31, 2022, with $424.9 million remaining at year-end.
Outlook, management commentary and risks
Management expected 2021 net product revenue to increase, citing continued TRIKAFTA uptake, KAFTRIO approvals, label expansions and wider access. It expected cost of sales as a percentage of product revenue to remain similar to 2020. No numerical 2021 revenue guidance is provided in the supplied filing text.
Pipeline priorities and anticipated milestones included 2021 data from Phase 2 trials of VX-864 for AAT deficiency and VX-147 for APOL1-mediated FSGS, and completion of enrollment in the CTX001 Phase 1/2 trials. Vertex discontinued VX-814 development in October 2020 after safety and pharmacokinetic findings. CTX001 interim results reported in December showed all seven treated TDT patients transfusion-independent at last follow-up and all three treated SCD patients free of vaso-occlusive crises through last follow-up; these early results are not confirmatory efficacy evidence.
Management reported that COVID-19 had not affected product demand or supply to date, but the pandemic could disrupt research, trials, operations, reimbursement and pricing. Major risks include dependence on CF medicines for nearly all revenue; reimbursement and pricing pressure, especially outside the U.S.; competition; clinical and regulatory uncertainty; third-party manufacturing and supply-chain reliance; and limited experience developing and manufacturing cell and genetic therapies. The filing reports no material legal proceedings, but describes Vertex’s patent-infringement suit against Sun Pharmaceutical over a proposed generic KALYDECO tablet.
Most important facts for investors to verify
- How much of the revenue and earnings trajectory depends on continued TRIKAFTA/KAFTRIO growth, and whether international reimbursement supports the expected expansion.
- Whether the reported growth in earnings is supported by recurring operations, separating product performance from strategic-investment gains and tax benefits.
- 2021 product revenue and expense guidance when available; the filing provides directional expectations but no numerical revenue forecast.
- Further clinical data and safety results for CTX001, VX-864 and VX-147, including whether interim findings are sustained in larger studies.
- Cash-flow conversion, rising future cash tax payments, lease obligations and planned share repurchases alongside continued R&D investment.
- Developments in CF pricing, generic competition and patent disputes, and the ability to scale third-party manufacturing for existing products and prospective genetic therapies.